Document is current
Any future updates will be listed below
-
Authors
Chopra, Teena https://orcid.org/0000-0003-1185-4549
Van Handel, Daniel
Baggott, Brian
Orenstein, Robert
Reveles, Kelly https://orcid.org/0000-0001-8880-4879
Guthmueller, Beth
Srivastava, Shivam
Khanna, Sahil
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01925417 at ClinicalTrials.govnct02299570 at ClinicalTrials.govDocuments that mention this clinical trial
Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection
https://doi.org/10.1080/13543784.2019.1581763
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies
https://doi.org/10.1007/s40121-026-01374-9
nct02589847 at ClinicalTrials.govDocuments that mention this clinical trial
Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
https://doi.org/10.1007/s40121-022-00744-3
Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection
https://doi.org/10.1080/13543784.2019.1581763
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies
https://doi.org/10.1007/s40121-026-01374-9
nct03244644 at ClinicalTrials.govDocuments that mention this clinical trial
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
https://doi.org/10.1186/s12879-022-07256-y
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies
https://doi.org/10.1007/s40121-026-01374-9
nct03931941 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
https://doi.org/10.1007/s40265-022-01797-x
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies
https://doi.org/10.1007/s40121-026-01374-9
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection
https://doi.org/10.1007/s40121-023-00907-w
nct05831189 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and Efficacy of Fecal Microbiota, Live-jslm for Prevention of Recurrent Clostridioides difficile Infection Among Hospitalized Participants in PUNCH CD3-OLS
https://doi.org/10.1007/s40121-026-01304-9
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies
https://doi.org/10.1007/s40121-026-01374-9
Safety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome
https://doi.org/10.1007/s40121-025-01208-0
Documents that mention this clinical trial
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies
https://doi.org/10.1007/s40121-026-01374-9
-
Funding
Funding for this research was provided by:
Ferring Pharmaceuticals, Inc
- License Information
-
More Information
Article History
Received: 25 February 2026
Accepted: 19 May 2026
First Online: 12 June 2026
Declarations
:
: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Teena Chopra is a speaker and consultant for Ferring Pharmaceuticals, Inc. Daniel Van Handel is on a speaker’s bureau for Ferring Pharmaceuticals, Inc. Brian Baggott declares that he has no conflicts of interest. Robert Orenstein participated on advisory boards for Rebiotix, Inc. Kelly Reveles serves as a scientific consultant for Ferring Pharmaceuticals, Inc. Sahil Khanna received research support from Vedanta and consulting fees from Takeda, Ferring, Rise, and ProbioTech. Beth Guthmueller was an employee of Ferring Pharmaceuticals, Inc. at the time this manuscript was developed. Shivam Srivastava is an employee of Ferring Pharmaceuticals A/S.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Institutional review board approval was not required. All participants provided consent for publication.
